Celliance Announces Leadership Team; Introduces Portfolio of Brand Nam

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    ATLANTA--(BUSINESS WIRE)--Feb. 10, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Celliance(TM) Corporation, its wholly-owned subsidiary, has appointed the members of the Celliance Leadership Team. The team members, who will report to David L. Bellitt, President, are collectively responsible for managing day-to-day customer-focused operations and for implementing overall corporate objectives. Appointments include the following:

    Joe Kozma, Vice President, Sales;
    Craig Brown, Vice President, Controller;
    Rick Srigley, Vice President, Contract Services;
    Chris Simonsen, Vice President, Research & Development;
    Jim Kramer, Acting Vice President, Operations;
    Diane Miller, Executive Director, Human Resources;
    Attilio Baldassi, Director, Marketing;
    Wayne Vaz, Director, Business Development & Strategic Planning.

    "We have assembled an experienced Leadership Team and a strategy for the future. With that foundation laid, we look forward to better serving our customers with the highest quality brand products and services," said Bellitt.
    "We are introducing new brand names for some of our established proprietary products which include Incelligent(TM), the Company's recombinant human insulin, Probumin(TM) BSA, a proprietary line of bovine serum albumin, and proprietary contract research services under the name Celliance BioServices(TM)."
    "By branding these key areas, Celliance is able to offer a unified, easily recognized line of products and services to more effectively adapt and grow to meet the rapidly changing needs of our customers," stated Attilio Baldassi, Director, Marketing.
    The new branding will be featured in the Company's catalog and in marketing communication materials and activities throughout 2005.
    Celliance(TM) offers an expanding array of bioprocessing products and services including diagnostic products, contract research and manufacturing services, and cell culture media supplements offering EX-CYTE(R), the largest selling cell growth supplement, Probumin(TM), a proprietary line of bovine serum albumin and Incelligent(TM), the Company's recombinant human insulin. It is also the world's leading provider of monoclonal antibodies for the blood typing industry. Celliance(TM) is a Serologicals company based in Atlanta, GA.

    Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, Georgia, is a global provider of biological products, enabling technologies and services to a diverse customer base that includes major life science companies and leading research institutions. Our customers use our products, technologies and services in a wide variety of their activities, including basic research, drug discovery, diagnosis and biomanufacturing. Our products, technologies and services are essential tools for research in key disciplines, including neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and molecular biology. In addition, the Company is the world's leading provider of monoclonal antibodies for the blood typing industry.
    Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.
    For more information, please visit our website: www.serologicals.com or www.celliancecorp.com.
    Serologicals is a registered trademark of Serologicals Royalty Company.

--30--JAH/at*

CONTACT: Serologicals Corporation, Atlanta Bill Davis, 678/728-2018

KEYWORD: GEORGIA INDUSTRY KEYWORD: BANKING BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Celliance Corporation

Copyright Business Wire 2005